Table 2 Subgroup results of OS and heterogeneity test
From: The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis
Heterogeneity test | |||||
|---|---|---|---|---|---|
Variables | Study number | HR (95% CI) | Q | P | I2(%) |
Total OS | 10 | 0.93 (0.83–1.04) | 22.95 | 0.006 | 60.8 |
Region | |||||
Asian | 3 | 1.26 (0.44–3.62) | 9.21 | 0.010 | 78.3 |
Caucasian | 7 | 0.93 (0.86–1.02) | 13.01 | 0.043 | 53.9 |
Sample size | |||||
>100 | 5 | 0.90 (0.55–1.47) | 15.35 | 0.004 | 73.9 |
<100 | 5 | 0.86 (0.58–1.26) | 7.44 | 0.114 | 46.2 |
Follow-up time (month) | |||||
>40 | 5 | 0.78 (0.50–1.21) | 9.38 | 0.052 | 57.4 |
<40 | 5 | 0.98 (0.62–1.55) | 13.33 | 0.010 | 70.0 |
Stage | |||||
Superficial | 3 | 0.79 (0.32–1.96) | 5.81 | 0.055 | 65.6 |
Muscle-invasive | 2 | 0.95 (0.91–0.99) | 0.56 | 0.456 | 0.0 |
All | 5 | 0.92 (0.54–1.55) | 16.17 | 0.003 | 75.3 |
Cut-off | |||||
>10% | 4 | 0.87 (0.55–1.39) | 6.07 | 0.108 | 50.5 |
≤10% | 5 | 0.98 (0.62–1.55) | 13.33 | 0.010 | 70.0 |